SCHEMBL25073045

SCHEMBL25073045

O=C(O)c1ccc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 6/20 0.50
▸ XDH P47989 2/20 0.47
▸ SLC22A12 Q96S37 1/20 0.47
▸ SIRT5 Q9NXA8 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ HPGD P15428 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ PTPN11 Q06124 1/20 0.42
▸ FABP4 P15090 1/20 0.41
▸ PYGL P06737 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073360 0.91 FABP4 (0.45) PFKFB3XDHSLC22A12ALDH1A1HPGD
SCHEMBL25073358 0.88 PTPN11 (0.43) PFKFB3XDHSLC22A12ALDH1A1HSD17B10
SCHEMBL25072767 0.87 FABP4 (0.48) PFKFB3MEN1KMT2AUSP2MAPT
SCHEMBL25073333 0.87 KDM4E (0.47) ALDH1A1HPGDKMT2AUSP2MAPT
SCHEMBL25072408 0.83 PTPN11 (0.51) ALDH1A1HPGDMEN1KMT2ATSHR
SCHEMBL25073032 0.83 HSD17B3 (0.59) ALDH1A1HSD17B10HPGDMEN1KMT2A
SCHEMBL25073308 0.82 P4HTM (0.49) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL30278475 0.82 PTPN11 (0.46) PFKFB3ALDH1A1HPGDMEN1KMT2A
SCHEMBL25073028 0.82 PTPN11 (0.44) PFKFB3ALDH1A1HPGDMEN1KMT2A
SCHEMBL25073280 0.82 PTPN11 (0.45) ALDH1A1HSD17B10HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 PFKFB3 1910/4885XDH 165/4885SLC22A12 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback